From new partnerships and launches, here are six developments from Globus Medical so far in 2025. 1. OsteoCentric Technologies entered into a non-exclusive licensing agreement with Globus Medical.

Globus Medical (NYSE:GMED) announced that its board of directors authorized a share repurchase program totaling up to $500 ...

To properly understand Globus Medical's profit results, we need to consider the US$200m expense attributed to unusual items. While deductions due to unusual items are disappointing in the first ...

Globus Medical’s board of directors authorized a share repurchase program of up to $500 million of the company’s outstanding common stock. Timing and number of repurchased shares will be determined by ...

Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors ...

Globus Medical stock is down today on an unexpectedly soft Q1 amid an earlier-than-planned integration with recently acquired ...

BTIG analyst Ryan Zimmerman lowered the firm’s price target on Globus Medical (GMED) to $77 from $88 and keeps a Buy rating on the shares. The ...

Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025.

Despite revenue challenges, Globus Medical Inc (GMED) reports significant free cash flow growth and strategic acquisitions to ...

Discover key Q1 2025 insights from Globus Medical, including revenue trends, the Nevro acquisition, free cash flow growth, and future strategies.